ClinicalTrials.gg
Enrolling by invitationNCT07295470SAFEUpdated Nov 4, 2026

Sleep and Activity For Eating Disorders

An interventional study of Actigraphy and Collection of biological parameters in Eating Disorders, Anorexia Nervosa and Bulimia Nervosa, sponsored by Istituto Auxologico Italiano. Enrolling by invitation at 1 site in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Istituto Auxologico Italiano · Not applicable, Interventional, and Basic science

How we know

Updated Nov 4, 2026Now Enrolling by invitationStart date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Feeding and Eating Disorders with a site in Italy — 13 open to participants now, 13 under way, none of them phase 3. Feeding and Eating Disorders · Italy.

Planned enrollment
9th of 18
75 · median 74
Started
2026
with 1 other
No phase
18 of 28
8 open now
Primary completion
2027-05
later than 12 of 12 live
Registered
24th of 28
by date
Lead sponsor
5 of 28
Istituto Auxologico Italiano

Among the 28 studies in Feeding and Eating Disorders with a site in Italy, this one is the 9th largest by planned enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2026, is one of 18 with no phase, reaches primary completion later than 12 of the 12 other live ones, and was the 24th registered.

Feeding and Eating Disorders

645 studies on the registry are indexed under Feeding and Eating Disorders; 151 are open to participants now.

Browse Feeding and Eating Disorders studies →

Open to participants now

13 of the 28 studies in Feeding and Eating Disorders with a site in Italy are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 99 Feeding and Eating Disorders studies recruiting now, 31 (31%) set no upper age limit and 66 (67%) stop at 75 or younger; 45 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Feeding and Eating Disorders with a site in Italy, or all of them as a file.
02

Study summary

The SAFE (i.e., Sleep and Activity For Eating disorders) study aims to investigate the characteristics of sleep, daytime activity, and circadian rhythms in a sample of patients with eating disorders-specifically anorexia nervosa, bulimia nervosa, and binge-eating disorder-as well as the relationship between these variables and physiological parameters (i.e., body mass index, hormone levels, blood chemistry parameters) and psychological parameters (i.e., levels of depression and anxiety, body image, eating-disorder symptoms).

Read the detailed description

The central aim of the study is to describe sleep characteristics in a population of patients with eating disorders (i.e., anorexia nervosa, bulimia nervosa, and binge-eating disorder) attending the Center for Eating and Nutrition Disorders of the Istituto Auxologico Italiano (Piancavallo branch) - San Giuseppe Hospital.

Sleep will be characterized through the following assessments:

  1. actigraphy combined with salivary melatonin measurement;
  2. collection of self-report data regarding sleep characteristics and dream content (e.g., sleep and dream diary);
  3. validated self-report questionnaires assessing sleep characteristics (Pittsburgh Sleep Quality Index - PSQI) and circadian rhythms (- reduced version of the Morningness-Eveningness Questionnaire - rMEQ).

Specifically, sleep characteristics will be assessed at home, during the month preceding admission to Piancavallo (Time 0), through:

  1. validated self-report questionnaires assessing sleep characteristics (PSQI) and circadian rhythms (rMEQ);
  2. collection of self-report data regarding sleep characteristics and dream content (e.g., sleep and dream diary), as well as actigraphy for at least one week.

Subsequently, throughout the entire inpatient stay (Time 1: first day of admission; Time 2: midpoint of the admission - 4 weeks; Time 3: the night before discharge), patients will be monitored using actigraphy and will undergo salivary melatonin measurement on the first and last day before discharge. During the same period, daily self-report data on sleep characteristics and dream content (e.g., sleep and dream diary) will be collected.

In these same patients, in addition to age, sex, anthropometric data, and blood chemistry parameters (including ghrelin, leptin, and orexin levels), as well as ongoing pharmacological treatment, the following will be assessed: presence and severity of body image distortion (Body Uneasiness Test - BUT , and Body Image Task - BIT), mood disorders (Beck's Depression Inventory - BDI, and Hospital Anxiety and Depression Scale - HADS), social anxiety related to physical appearance (Social Appearance Anxiety Scale - SAAS), severity of the eating disorder (Eating Disorder Inventory-3 - EDI-3, Yale-Food Addiction Scale - YFAS, and Binge Eating Scale - BES), intensity of the urge to engage in physical activity (State Urge to be Physically Active Questionnaire - SUPAQ), and individual differences in the expression of personality traits (HEXACO adjectives list). Measurements obtained through these psychometric tests will be collected at three timepoints: upon admission to the unit for rehabilitation (Time 1), around the midpoint of the rehabilitation program (Time 2: 4 weeks after admission), and at discharge (Time 3).

The secondary objectives will also include the following:

  • Assessing the correlation of the above parameters with the intensity, duration, and circadian distribution of daytime physical activity using actigraphy and validated scales (SUPAQ); actigraphy will also allow the evaluation of several nighttime sleep parameters: sleep duration, number of awakenings, and sleep efficiency (e.g., ratio of sleep time to time in bed);
  • Assessing the relationship between sleep patterns and the degree of body image distortion as measured through the BIT, which examines body-part metrics and allows calculation of the distortion index between real body measurements and those implicitly perceived by the subject, and the BUT, an additional measure of perceived inadequacy regarding one's body;
  • Assessing the influence of mood disorders measured through structured interviews and standardized questionnaires (BDI-II and HADS) on sleep characteristics and eating disorder severity in the population described above;
  • Assessing the influence of chronotype (e.g., morning, evening, or intermediate), investigated through the rMEQ questionnaire, on eating disorder symptomatology and on the expression of different personality traits, assessed through self-report questionnaires (HEXACO).
03

Conditions studied

  • Eating Disorders
  • Anorexia Nervosa
  • Bulimia Nervosa
  • Binge Eating Disorder

Keywords

  • Sleep
  • Circadian rhythms
  • Eating disorders
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • a) Age over 18 and under 65;
  • b) Diagnosis of anorexia nervosa, bulimia nervosa, or binge-eating disorder, as indicated by criteria;
  • c) Adherence to the rehabilitation program.

Exclusion criteria

Exclusion Criteria:

  • a) Presence of severe bradycardia (BPM \< 35);
  • b) Severe malnutrition ( \< 10);
  • c) Presence of severe psychopathology other than the eating disorder (e.g., schizophrenia);
  • d) Need to modify psychotropic or sleep-inducing pharmacological therapy during the rehabilitation program.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Other
    Patients with anorexia nervosa

    Examinations of sleep, circadian rhythms, physical activity and psychological features

    Device: Actigraphy · Biological: Collection of biological parameters · Other: Psychological testing

  • Other
    Patients with bulimia nervosa

    Examinations of sleep, circadian rhythms, physical activity and psychological features

    Device: Actigraphy · Biological: Collection of biological parameters · Other: Psychological testing

  • Other
    Patients with binge-eating disorder

    Examinations of sleep, circadian rhythms, physical activity and psychological features

    Device: Actigraphy · Biological: Collection of biological parameters · Other: Psychological testing

Interventions

  • DeviceActigraphy

    The actigraph is a non-invasive device used to measure sleep-wake rhythms based on the recording of motor activity over a 24-hour period (Acker et al., 2021). Since it is easy to handle due to its physical characteristics, it can be worn for extended periods and therefore allows the collection of data related to activity and rest phases, as well as circadian rhythms. Specifically, the use of this method allows the collection of measures relating both to daytime motor activity (i.e., intensity, duration, and circadian distribution) and to nighttime sleep (i.e., duration, sleep-onset latency, wake period, number of awakenings, efficiency index, sleep and wake times).

    Also known as: Actigraphic measurements of sleep

  • BiologicalCollection of biological parameters

    Some medical parameters will be collected, including blood pressure, heart rate, respiratory rate, blood levels of ghrelin, leptin, and orexin, as well as salivary melatonin levels.

    Also known as: Biological draws (blood and salivary)

  • OtherPsychological testing

    Participants will be asked to complete: a) Pittsburgh Sleep Quality Index (to measure subjective sleep quality); b) Morningness-Eveningness questionnaire (to measure the chronotype); c) Body Uneasiness Test (to measure body image uneasiness); d) Body Image Task (to measure the implicit perception of body image); e) Eating Disorder Inventory-3, Binge Eating Scale, Yale Food Addiction Scale (to measure the severity of eating symptoms); f) Beck Depression Inventory - II, Hospital anxiety and Depression Scale, Social Appearance Anxiety Scale (to measure depression levels); g) State Urge to be Physically Active Questionnaire (to measure physical activity levels); h) HEXACO list of adjectives (to evaluate personality traits).

    Also known as: Psychological testing through self-report measures or instruments administered by clinicians

06

What researchers measure

Primary outcomes

  1. Sleep efficiency (SE)

    Sleep efficiency will be detected through actigraphic measurements and will be compared either within and among groups.

    Time frame: A week before the rehabilitation recovery (Time 0), at the beginning of the recovery (Time 1), half of the recovery (Time 2 - after 4 weeks from Time 1) and at the end of the recovery (Time 3 - 7 weeks from Time 1).

  2. Chronotype

    Chronotype is the propensity for the individual to engage in certain activities (i.e., sleep) at a particular time during a 24-hour period. It will be detected through a self-report measure, the Morningness-Eveningness Questionnaire, in its reduced version. The scale is composed by 5 items evaluating: a) preferred time for waking up, b) preferred time for going to bed, c) subjective peak alertness during the day, d) ease of getting out of bed, and e) self-assessment of being a "morning" or "evening" type. The total score ranges from 4 to 26, with the following threshold and interpretation: a) 4-10: Evening type, b) 11-18: Intermediate type, c) 19-26: Morning type.

    Time frame: A week before the rehabilitation recovery (Time 0), at the beginning of the recovery (Time 1), half of the recovery (Time 2 - after 4 weeks from Time 1) and at the end of the recovery (Time 3 - 7 weeks from Time 1).

  3. Orexin Levels

    Levels of orexin detected through blood exams.

    Time frame: At the beginning of the recovery (Time 1) and at the end of the recovery (Time 3 - 7 weeks from Time 1).

07

Study locations

1 site
  • Istituto Auxologico Italiano - S. Giuseppe Hospital
    Verbania, VB 28824, Italy
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for May 2027, 10 months after the start.

Of 267 non-industry interventional studies with no phase under Feeding and Eating Disorders, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 10 months is below that.

Counting every sponsor, half of 272 studies reached it within 28 months; a quarter within 14 and three quarters within 49.

Start moved once since we started tracking on Sep 25, 2026: Feb 2026 → Jul 2026, on Nov 4, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2025
First posted
Dec 19, 2025
StartActual
Jul 1, 2026was Feb 2026
Primary completionEst.
May 2027
CompletionEst.
Jul 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Enrolling by invitation
changed Nov 4, 2026
Start date
Feb 2026→Jul 1, 2026 (actual)
Nov 4, 2026
Contact
No study contact listed any more: removed g•••@auxologico.it · •••8693; removed c•••@auxologico.it
Nov 4, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Istituto Auxologico Italiano - S. Giuseppe Hospital · Verbania, ItalyContact removed c•••@auxologico.it · •••9580
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Not yet recruiting→Enrolling by invitation
    Start date Feb 2026→Jul 1, 2026 (now actual)
    Contact No study contact listed any more: removed g•••@auxologico.it · •••8693; removed c•••@auxologico.it
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Istituto Auxologico Italiano - S. Giuseppe Hospital · Verbania, ItalyContact removed c•••@auxologico.it · •••9580
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07295470
Responsible party
Sponsor
First posted
Dec 19, 2025
Start date
Jul 1, 2026
Primary completion
May 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Luigi De Gennaro
study director · University of Roma La Sapienza
Leonardo Mendolicchio, MD
study director · Istituto Auxologico Italiano
Serena Scarpelli, PhD
study director · University of Roma La Sapienza

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion